Background. The purpose of this study was to determine the relevance of clinical data, apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) from dynamic susceptibility contrast (DSC) perfusion and the volume transfer constant (k trans ) from dynamic contrast-enhanced (DCE) perfusion for predicting overall survival (OS) and progression-free survival (PFS) in newly diagnosed treatment-naïve glioblastoma patients.
As an integral part of the diagnostic process for patients with glioblastomas, MRI is a noninvasive tool for providing information on the physiologic properties of the tumor. Therefore, it has been widely investigated for its ability to estimate baseline risk and prognosis, which are crucial information for assigning patients to optimized, patient-individual treatment regimens or subgroups of clinical trials. Features of contrast-enhanced T1-weighted images (cT1) and T2-weighted images (tumor volume, presence of contrast enhancement, or extensive edema) 1 -5 as well as a combination of functional parameters derived from diffusion-weighted imaging (DWI), dynamic susceptibility contrast-enhanced MR perfusion (DSC), and dynamic contrast-enhanced MR perfusion (DCE) have been examined as potential predictors of patient outcome. 6 -12 The most commonly used DWI-derived parameter is the apparent diffusion coefficient (ADC), which measures the diffusion of water molecules in tissue. Low ADC values are suggested to correlate with features of aggressiveness, recurrence, and poor survival in astrocytic tumors. 6 -10,13 -19 Relative cerebral blood volume (rCBV) is calculated on the basis of DSC MR perfusion. High rCBV values (with 2 exceptions 7, 8 ) have been shown to be associated with worse outcome, 9,11,12,20 -31 which is commonly attributed to the fact that tumor-induced angiogenesis causes increased blood flow, hence marking aggressive tumor growth. A combination of diffusion-and perfusion-imaging also allows identifying different growth patterns associated with prognosis. 32 DCE MR perfusion-derived k trans , the volume transfer constant of contrast agent from a plasma space to an extravascular extracellular space, reflects both flow and vascular permeability within brain tissue. 33 It has shown to correlate with glioma grade 34 and allows distinguishing recurrent glioma from radiation necrosis. 35 While one study reported that low k trans predicts worse outcome in glioblastoma patients, 23 2 other studies stated that elevated k trans values are associated with worse outcome. 28, 36 In line with the recently published consensus recommendations for brain tumor imaging protocols, 37 our institution routinely includes all of the above-mentioned MRI-sequences in patients with suspected intra-axial lesions. Therefore, if proven useful, they will be readily available as potential biomarkers for every patient in the future.
Our aim was to examine a large and homogenous patient collective of exclusively newly diagnosed glioblastoma patients and thus provide a comprehensive analysis of clinical and imaging parameters that are suggested as predictors of outcome in glioblastoma patients at the time of diagnosis.
Materials and Methods

Patients
This retrospective study was approved by our local ethics committee (ethics approval number, S-320/2012). By screening our database from July 2009 to August 2014, we identified 85 patients who had received an MRI examination including T1, T2, DSC, and DCE perfusion MRI and diffusion (ADC) sequences prior to surgery (median 3 [0 -23] days) and were thereafter diagnosed with primary glioblastoma (IDH-wild-type). Another 48 patients with primary glioblastoma had received all sequences except for DCE perfusion. Eight patients had to be excluded after postprocessing due to insufficient image quality or motion artifacts, yielding a total of 125 patients who were enrolled in our analysis. We obtained data about the age at diagnosis, sex, extent of tumor resection (EOR, defined as gross total resection, subtotal resection, or biopsy on postoperative MRI within 72 hours after surgery), adjuvant therapy regimen, KPS closest to surgery, and MGMT-promoter status (available for 51 patients). Overall survival (OS) was calculated as the time from surgery to death or date of inquiry at the registration office where the patient was reported to be alive. Progression-free survival (PFS) was determined as the time from surgery to death, progress according to RANO criteria, and/or clinical progress as reported in follow-up visits. At the date of the last inquiry on October 1, 2014, 42 patients were still alive, and 19 patients had not experienced progression of their disease and were therefore censored.
Magnetic Resonance Imaging
All patients were examined a median of 3 days prior to surgery in a 3 Tesla MRI scanner according to the standardized tumor protocol at our institution (TrioTIM or VERIO, Siemens Healthcare) as described previously. 28 After the third dynamic acquisition, a standard dose (0.1 mmol/kg body weight) of gadoterate meglumine (Gd-DOTA, Dotarem) was injected as a bolus through a pneumatically driven injection pump at an injection rate of 5 mL/s. After completion of the DCE-MRI sequence, another standard dose (0.1 mmol/kg body weight) of contrast agent was administered and followed by acquisition of DSC-MRI, obtained as a 2D-multislice, T2*-weighted gradient-echo EPI sequence (TR ¼ 2220 ms, TE ¼ 36 ms, pixel size 1.797 mm/1.797 mm, image matrix 128 ×128, slice thickness 5 mm, flip angle 908, FoV 240×240 mm) as described previously. 38 -40 Subsequently, a postcontrast T1-weighted 3D magnetization-prepared rapid acquisition gradient echo (cT1) sequence was performed with TR ¼ 1710 ms, TE ¼ 4.04 ms, pixel size 0.5 mm/0.5 mm, image matrix 512× 512, slice thickness 1.3 mm, flip angle 158, FoV 256×256 mm, and inversion time 1100 ms.
Postprocessing
Postprocessing of DSC and DCE-MRI data and generation of rCBV and k trans maps were performed with dedicated software (Olea Sphere v2.3, Olea Medical) as described previously. 39, 40 Next, image registration was performed with the FMRIB software library (FSL, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL 41 ) as described previously. 39, 42 First, brain voxels were isolated by generating a binary brain mask from the T1-volume using the brain extraction tool 43 and transferred to all other imaging volumes (cT1, FLAIR, DWI, ADC map, first temporal volume of DSC-MRI raw data, rCBV map) for each patient. These image volumes were then registered to the brain-extracted T1-volume as the reference sequence (slice thickness 1.3 mm) using the linear image registration tool 44, 45 with a mutual information algorithm and a 6 degree of freedom transformation. T1 subtraction volumes (subT1) were generated by voxel-wise subtraction of the T1 from the cT1 volume. obvious leukoaraiosis (ie, presence of bilaterally symmetrical, patchy, or confluent periventricular white matter hyperintensities) using a region-growing segmentation algorithm implemented in ITK-SNAP (www.itksnap.org 46 ) as described previously (for illustration please compare Fig. 1) . 39, 42 The presurgical tumor volume was defined as all hyperintense tumor parts on FLAIR images including CE, ED, and necrotic parts.
Extraction of rCBV, k trans and ADC values from the CE-and ED-VOI was performed with customized in-house software implemented in Matlab as described previously. 39, 42 The first volumes of the DWI and DSC-MRI raw data were thresholded to determine regions of prohibitive signal loss near susceptibility interfaces such as the skull base, and the tumor segmentations were modified by removal of low-signal regions. Gaussian normalization of rCBV, k trans , and ADC maps was performed with voxel-wise division of the corresponding map through the standard deviation of the normal-appearing brain volume (derived from the inverted FLAIR-hyperintense tumor segmentations) 47 prior to calculation of appropriate percentiles (10th and 90th) from the Gaussian-normalized rCBV, k trans , and ADC histograms of the CE and ED-VOI.
Statistical Analysis
All statistical analyses were performed in R (Version 3.2.3). P values ≤.05 were considered significant. Model assumptions for the Cox regression analysis were checked.
Univariate Cox regression analysis was performed for PFS and OS with the following variables: age, KPS, sex, presurgical tumor volume, EOR, 10th percentile ADC, 90th percentile rCBV, 90th percentile k trans in contrast enhancement (CE), and peritumoral edema (ED). Hazard ratios and corresponding 95% confidence intervals were calculated.
For the multivariable Cox regression analysis, we included age, KPS, sex, presurgical tumor volume, EOR, 10th percentile ADC, 90th percentile rCBV in CE, and ED. As there were about 38% missing data in k trans values, we refrained from including this variable in the multivariable analysis. Again, hazard ratios for each regressor and corresponding 95% confidence intervals were calculated. Moreover, we used the Gö nen & Heller concordance probability estimate (CPE) 48 to evaluate the predictive power of our multivariable Cox proportional hazards models.
Results
Clinical Data
Overall, 125 patients were included in the analysis. There were 50 female and 75 male patients with a median age of 63 (37 -71) years. Median OS was 10.7 months (95% CI: 8.9-13.3], 42 patients still alive and thus censored), and mean PFS was 4.8 months (95% CI: 4.1 -6.3; 19 patients censored). Patients underwent surgical intervention as follows: 41% gross total resection (GTR), 38% subtotal resection (STR), and 21% biopsy (B). The tumor was most often localized in the frontal lobe (28%), followed by temporal lobe (26%), multifocally (2 or more lobes affected; 18%), parietal lobe (15%), occipital lobe (7%), or centrally in the basal ganglia/thalamus (6%). The adjuvant therapy regimen consisted of radiotherapy plus temozolomide in 51% of patients; in another 12% of patients, a drug within a clinical study was added to this scheme . 8% in another 12% of patients received temozolomide only, 21% received radiotherapy only, and 6% received palliative care. The adjuvant therapy regimen was not documented for 2 patients. The median KPS was 80 (20 -100) points. Fifty-one patients had their KPS score documented prior to surgery, and postoperative KPS was available for 74 patients (median ¼ 7+5 days after surgery). O6-methyl-guanine DNA methyltransferase (MGMT)-promoter status was documented in 42% of patients (N ¼ 53), of whom 47% were hypermethylated. Median ki67 was 20 (5;80)%.
Cox Regression Models
Model assumptions for the Cox regression analysis were checked by testing the proportional hazard assumption and the linear relationship between covariates and log hazard. As expected, the proportional hazard assumption was violated by the covariate "age" in both multivariable analyses, with its hazard increasing steadily over time. However, the proportional hazard assumption for the whole models remained fulfilled. Linearity assumption of all covariates was confirmed for OS and PFS.
In the univariate Cox regression model, age (HR ¼ 1.03, P , .01), KPS (HR ¼ 0.85, P , .01), and EOR (GTR vs B; HR ¼ 2.04, P , .01) were significant for PFS, while EOR (GTR versus STR; HR ¼ 1.54, P ¼ .05), and rCBV CE (HR ¼ 1.12, P ¼ .08) showed a tendency towards significance (Table 1) 
Discussion
A principal finding of this study is that MRI parameters help to predict OS in a univariate Cox regression analysis, while their relevance is outperformed by clinical parameters when included in a multivariable Cox regression analysis. Increased rCBV CE was a predictive marker only for PFS.
In looking at the clinical parameters, a somewhat surprising effect is that females had a longer PFS and OS in our multivariable analysis. While age, KPS, EOR, and adjuvant therapy do not differ significantly in our cohort between the sexes, 80% of females for whom an MGMT-promoter status was documented (N ¼ 20) were hypermethylated, while only 27% of males were hypermethylated (N ¼ 35). Since MGMT-promoter hypermethylation is associated with better response to chemotherapy, this might be the reason why the females in our cohort had a better outcome. Unfortunately, MGMT-promoter status was only documented for 42% of patients, but its uneven distribution among the sexes might be a possible explanation for the effect of sex on survival. Abbreviations: ADC, apparent diffusion coefficient; B, biopsy; CE, contrast enhancement; ED, peritumoral edema; EOR, extent of resection; GTR, gross total resection; HR, hazard ratio; KPS, Karnofsky performance scale; K trans , volume transfer constant; N, patient number included in particular analysis; variations are due to missing values; rCBV, relative cerebral blood volume; STR, subtotal resection; y, year. a Preoperative volume of the whole tumor hyperintensity on FLAIR including necrosis, contrast enhancement and peritumoral edema.
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Concerning the MRI parameters, low ADC values and high rCBV values in contrast enhancement and peritumoral edema were associated with shorter OS in our univariate Cox regression analysis. Increased rCBV CE was also associated with shorter PFS in the multivariable model. This is in accordance with many studies that found decreased ADC values 6 -10,14,16 -19 and high rCBV values 9,12,20 -31 to be associated with worse outcome in glioma.
While there is a variety of studies looking at MR characteristics to predict survival following resection, 9,10 radiochemotherapy, 11 or at the time of recurrence, 39, 40 there are only 4 studies that have included both diffusion and perfusion parameters for a survival analysis in astrocytic brain tumors before surgery or treatment. 6 -8,12 Summarizing their findings, rCBV was found to be predictive of OS (in a univariate analysis) in one study. 12 Four studies found diffusion-derived MRI parameters to be significant for OS even if included in a multivariable analysis. 6 -8 In our multivariable analysis, rCBV ED trended towards significance for OS, and rCBV CE was the only significant MRI parameter for PFS. Diffusion-derived MRI parameters did not predict survival. The main reason why our results differ from previously published multivariable analyses is probably the implementation of other methodical and statistical approaches with which we hoped to overcome some of the limitations of the previously mentioned works.
First, with 125 primary (IDH-wildtype) WHO IV glioblastoma patients, our study is among those with the largest and most homogenous patient collective. Hence, we avoid including gliomas of different grades with varying biological properties.
Second, we chose to perform a histogram analysis based on a manually controlled, semiautomatic segmentation of the whole tumor volume as opposed to placing singular regions of interest in visually abnormal areas of the functional MRI maps. We consider this to be an observer-independent, reproducible, and well-established method in this context. 7 -10,17,28,49 Even though MRI cannot account for the microscopic heterogeneity inherent in all glioblastomas, we are confident that our approach is the most reliable for noninvasive characterization of glioblastoma to date.
Third, the use of continuous variables rather than binary variables, both as regressors and endpoints in a multivariable regression approach, will yield unbiased estimators that are adjusted for potential effects of the other covariates. Together with varying selections of clinical and imaging parameters that were entered into the analysis, we consider this to be the main explanation why our results differ from previously published works.
Limitations of our study are its retrospective design, censored information, and some missing values when patient records were incomplete or patients had been referred to other institutions. The concordance indices of our multivariable models indicated an acceptable predictive ability. They could have probably been improved by including the received therapy regimens in the model. We chose not to do so because this information would not have been available for predicting survival at the time of diagnosis. We also refrained from retrospectively selecting patients with uniform adjuvant therapy regimens because that might have excluded those with particularly good or poor survival who were allocated to nonstandardized treatment regimens.
While age, performance status, and extent of resection remain the relevant prognostic markers at the time of diagnosis when measured against singular physiologic MRI parameters, the next step would be to investigate enhanced methodical approaches such as radiomics 50, 51 (preferably in longitudinal studies). Additionally, a combination of radiological and histopathological/molecular features in the emerging field of radiogenomics 52, 53 might help to establish markers that complement clinical information. Abbreviations: ADC, apparent diffusion coefficient; B, biopsy; CE, contrast enhancement; CPE, concordance probability estimate by Gö nen und Heller; ED, peritumoral edema; EOR, extent of resection; GTR, gross total resection; HR, hazard ratio; KPS, Karnofsky performance scale; K trans , volume transfer constant; rCBV, relative cerebral blood volume; STR, subtotal resection; y, year. a Preoperative volume of the whole tumor hyperintensity on FLAIR including necrosis, contrast enhancement, and peritumoral edema.
Conclusion
The presented volume of interest-based histogram analysis of 125 patients with glioblastoma showed that MRI parameters help to predict OS in a univariate Cox regression analysis and that increased rCBV CE is associated with shorter PFS in the multivariable model. In summary, however, our findings suggest that the relevance of MRI parameters is outperformed by clinical parameters in a multivariable analysis, which limits their prognostic value for survival prediction at the time of initial diagnosis.
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